Zafgen, Inc. (NASDAQ:ZFGN) Analyst Ratings as of May 3, 2018

May 3, 2018 - By Lena Young

Zafgen, Inc. (NASDAQ:ZFGN) Corporate Logo

Zafgen, Inc. (NASDAQ:ZFGN) Ratings Coverage

Total analysts of 2 have positions in Zafgen (NASDAQ:ZFGN) as follows: 1 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 50%. Since January 5, 2018 according to StockzIntelligence Inc Zafgen has 2 analyst reports. Listed here are Zafgen, Inc. (NASDAQ:ZFGN) PTs and latest ratings.

07/03/2018 Broker: JMP Securities Rating: Buy New Target: $20.0
05/01/2018 Broker: Cowen & Co Rating: Hold

The stock increased 3.08% or $0.21 during the last trading session, hitting $7.02.Currently Zafgen, Inc. is uptrending after 54.27% change in last May 3, 2017. ZFGN has 75,181 shares volume. The stock outperformed the S&P 500 by 42.72%.

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity.The firm is worth $193.49 million. The companyÂ’s lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases.Last it reported negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: